Shamburg News · 8-K filed Nov 16, 2026, 6:03 AM EST

Aclaris Therapeutics Phase 2 bosakitug atopic dermatitis trial misses primary endpoint

ACRS · Aclaris Therapeutics, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: high

Aclaris Therapeutics reported top line results from the Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis, stating the trial did not achieve its primary or secondary endpoints. Pharmacodynamic results showed robust TSLP target engagement and biomarker downregulation, and the drug was generally well tolerated. The company also announced initiation of the Phase 2b ALPHA trial of modzatinib in lichen planus, expects ALPHA oral erosive lichen planus top line results in the second half of 2027, and plans an ATI-9494 IND filing in the fourth quarter of 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-127478.

Written from the filing by Shamburg Markets. Figures are as reported by the company.